publication date: Oct. 5, 2018

Trials & Tribulations

How tumor-specific modulation frequencies were discovered

Boris Pasche

By Boris Pasche

Charles L. Spurr Professor of Medicine,

Chairman, Department of Cancer Biology,

Director, Comprehensive Cancer Center of Wake Forest University


In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.

We had worked together for the previous 15 years, developing a medical device emitting low levels 27 MHz radiofrequency electromagnetic fields with the goal to treat insomnia. This work had been fruitful, as we had identified specific modulation frequencies with a sleep-restoring effect in humans(1-3).

Despite clinical evidence of efficacy from a multicenter randomized study conducted in the US that included 106 patients with chronic insomnia(4), there were lingering concerns about the long-term toxicity of radiofrequency electromagnetic fields because of the emerging cell phone controversy in the 1990s, which suggested that long-term use of cell phones was associated with increased cancer risk, especially with respect to brain tumors.

Symtonic, the company built around this technology, was not able to find partners to bring this device to the market as most pharmaceutical companies were concerned about the long-term liability of a novel technology making use of radiofrequency electromagnetic fields.

Following completion of my clinical training in Hematology/Oncology at … Continue reading How tumor-specific modulation frequencies were discovered

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.